Point72 Asset Management
CTNM

Point72 Asset Management’s Contineum Therapeutics CTNM Stock Holding History

Point72 Asset Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Sell
25,779
-59,112
-70% -$775K ﹤0.01% 3244
2026
Q1 		$1.11M Sell
84,891
-674,336
-89% -$9.04M ﹤0.01% 2707
2025
Q4 		$8.68M Buy
759,227
+391,582
+107% +$4.47M 0.01% 1445
2025
Q3 		$4.32M Sell
367,645
-20,994
-5% -$169K 0.01% 1121
2025
Q2 		$1.54M Buy
+388,639
New +$1.69M ﹤0.01% 1410

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Point72 Asset Management's CTNM Position: Q2 2026 in Review

Point72 Asset Management reduced its Contineum Therapeutics (CTNM) stake by 70% in Q2 2026, selling an estimated $775K and leaving 25,779 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #3244.

Point72 Asset Management first reported a position in CTNM in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.68M in Q4 2025. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Point72 Asset Management held 25,779 shares of Contineum Therapeutics worth $423K as of Q2 2026.
  • Point72 Asset Management sold 59,112 Contineum Therapeutics shares in Q2 2026, an estimated $775K.
  • Contineum Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3244 holding.
  • Point72 Asset Management first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Point72 Asset Management's Contineum Therapeutics position peaked at $8.68M in Q4 2025.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.